Natus Medical Incorporated, a leading provider of medical device solutions focused on the screening, diagnosis and treatment of central nervous and sensory system disorders, has announced the closing of its acquisition of Micromed Holding SAS (Micromed), a global provider of neurophysiology solutions. Micromed products will be added to the Natus Neuro portfolio and developed alongside Natus technologies. "We are thrilled to complete this deal and move forward combining the Natus and Micromed teams and product portfolios," said Austin Noll, Natus President and leader of Natus Neuro. "Together we will be able to provide our neuroscience customers a more comprehensive product offering and unrivaled global service and support through the increased breadth and depth of our combined resources." The Natus legacy of over 85 years of neurodiagnostic leadership will grow through the addition of the complete line of Micromed solutions to comprise an even stronger portfolio of products across electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU) monitoring. Together the products and organizational experience will bring incremental value to customers around the world, while also providing a strong platform for new product development. "The Micromed team is excited to bring our passion, our experience, our products and our European leadership to Natus," said Cristiano Rizzo, General Manager of Micromed. "As we expand through the extensive Natus structure, we will continue to cultivate the customer and key opinion leader relationships that we have established at Micromed over the years." This acquisition is the first by Natus since its de-listing from the NASDAQ in July, 2022 and reflects a commitment to invest in growth. "The acquisition of Micromed is the first transaction in our acquisition roadmap to build leading companies in both Neuro and Sensory under the Natus umbrella," said Thomas J. Sullivan, Natus Chief Executive Officer. "This is a significant milestone for Natus, our customers and their patients." Newly merged organization brings together innovative neurodiagnostic and neuromonitoring solutions and experienced teams to offer a broader portfolio of products, services and support to customers worldwide
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!